Please provide your email address to receive an email when new articles are posted on . Patients with asthma who switched from a metered-dose inhaler to a dry-powder inhaler cut their inhaler carbon ...

GlaxoSmithKline plc today announced that the Food and Drug Administration has approved Arnuity™ Ellipta® (fluticasone furoate inhalation powder), a once-daily inhaled corticosteroid (ICS) medicine for ...

Shifting from a metered-dose inhaler to a dry-powder inhaler for chronic obstructive pulmonary disease (COPD) and asthma in one healthcare system formulary led to increased healthcare utilization, a ...

Switching asthma patients from a pressurised metered dose inhaler (pMDI) to a dry powder inhaler (DPI) for maintenance therapy more than halves their carbon footprint without loss of asthma control, ...

Adherium, a New Zealand-based maker of connected respiratory medical devices, has received the US Food and Drug Administration's 510(k) clearance for connecting its digital monitoring platform with ...

The FINANCIAL — GlaxoSmithKline plc and Theravance, Inc. on April 30 announced that the US Food and Drug Administration (FDA) has approved BREO ELLIPTA (fluticasone furoate/vilantero for the ...

Please provide your email address to receive an email when new articles are posted on . Almost all of the estimated 1.15 MMT of CO 2 equivalent emissions in 2022 came from metered-dose inhalers. The ...

If you have not heard already, one of the most popular inhalers has been discontinued by its manufacturer since January 1. GlaxoSmithKline (GSK) has stopped producing Flovent, which comes as a metered ...

DUBLIN, Sept. 24, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") today highlighted that the European Medicines Agency's (EMA) Committee for Medicinal Products ...

There was a notable gap in effectiveness between metered-dose and dry-powder formulations of single-inhaler triple therapy for chronic obstructive pulmonary disease (COPD), according to real-world ...

The pros and cons to using a dry powder inhaler as treatment for chronic obstructive pulmonary disease. Neil Minkoff, MD: Dr Drummond, we’ve talked a little bit about the differences. You brought some ...